Trial Profile
Phase II study of letrozole (Femara) and celecoxib (Celebrex) in postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 17 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 17 Nov 2009 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
- 17 Nov 2009 Actual initiation date changed from Mar 2004 to Jan 2005 as reported by ClinicalTrials.gov.